Parceria bem-sucedida entre Aché, Phytobios e CNPEM, cofinanciado pela EMBRAPII, resulta em projeto voltado à pesquisa de moléculas com ação anticâncer a partir da biodiversidade.
This project, in partnership with the startup Nintx and funding from EMBRAPII, is intended to develop pharmaceutical candidates to treat viral infections caused by coronaviruses.
In partnership with the startup Nintx and with funding from EMBRAPII, this project is intended to develop pharmaceutical candidates from natural products to treat cardiac and hepatic illnesses.
This third project in partnership with Nintx and co-funding from EMBRAPII works to develop pharmaceuticals from natural products that can boost immunotherapy to treat cancer.
The project, entitled “Aliança Dor” [Pain Alliance], is co-funded by EMBRAPII within the Basic Bioeconomy Funding Alliance modality and also involves the Cristália and Phytobios companies, along with the startup Nintx and the FMRP/USP EMBRAPII unit.
Following on from the 3DBS project concluded in 2022, CNPEM (LNBio) has started a new partnership with the startup entitled “Validation of a bioprinted human skin equivalent”.
This project, which ran from 2018 to 2022, was dedicated to developing a dermocosmetic to treat and regenerate the skin with anti-aging effects, from plant extracts obtained from Brazilian flora.
This project, which ran from 2019 to 2022, worked to develop alternatives to animal testing for toxicological assays using human microphysiological systems involving simultaneous cultivation of three different 3D culture models (skin, liver, and intestinal barrier) on a single chip to evaluate the toxicity of topical treatments.